James Kent | Specialist Procurement Pharmacist London & East of England
NHS England

James Kent, Specialist Procurement Pharmacist  London & East of England, NHS England

James Kent worked for many years within the acute sector of the NHS, most recently as Clinical Lead Pharmacist and later Chief Pharmacist at Southend Hospital NHS Trust. From 2011-2017 he was also seconded to an organisation called PrescQIPP as the Secondary Care  Lead. This organisation seeks to support the NHS Medicines Optimisation agenda through the delivery of evidence based resources. This role allowed him to focus on a variety of key topics, the most significant of which was the introduction of biosimilars within the NHS.
James now works as the  Regional Medicines Procurement Specialist for London and the East of England. This position has allowed James to continue on his mission to maximise biosimilar usage for the benefit of both NHS providers and commissioners. This work is facilitated by his membership of the National Biosimilars Programme Board. He is also the Chair of the Branded and Biosimilars Subgroup which sits under the Pharmaceutical Market Support Group (PMSG).


Biosimilars Day 1 - Tuesday 29th October 2018 @ 09:40

International stakeholders panel discussion: What does it take to get biosimilars moving in a country?

    sting of industry panellists, physicians, pharmacists, patient advocacy groups, payers, regulators and health authorities, the 360° Perspective Panel allows the whole industry to come together to discuss and debate the sector’s most pertinent topics of the day.
  • With no guarantee that physicians will prescribe biosimilars interchangeably with reference products, what more does the industry need to do to encourage biosimilar uptake within healthcare?
  • What can we learn from gain-sharing practices? Carrot & stick models, which works better?
  • How influential are payers in the speed in which biosimilars are taken up in healthcare systems?
  • How does the industry envisage overcoming the challenge that patient communities are generally unaware of this new, yet important, category of medicines

Biosimilars Day 1 - Tuesday 29th October 2018 @ 11:20

Breakout sessions

WORKSHOP 1Understanding issues around physician education and uptakeHost: Jonathan Underhill, Medicines Clinical Adviser, Medicines and Technologies Programme (MTP), NICEJatinder Harchowal, Chief Pharmacist / Clinical Director, Medicines Management & Clinical Support Services Business Unit, Pharmacy Dept, The Royal Marsden NHS Foundation TrustJames Kent, Regional medicine procurement specialist East of England, NHS EnglandCaroline Boulliat, Member of Biosimilar Medicine Programme Board, NHS England, NHS Clinical Commissioners, NICEWORKSHOP 2WHO Guidelines on Global reference productIngrid Schwarzenberger, Head Global Regulatory Affairs, Sandoz BiopharmaceuticalsSuzette Cox, Senior Director International - Biosimilar Medicines Group, Medicines for EuropeMareike Ostertag, Director Science & Regulatory policy, NovartisROUNDTABLE 1Tackling IP and Legal challengesStacie Ropka, Partner, Axinn, Veltrop & Harkrider LLPROUNDTABLE 2Working with multi-cultural, global virtual teams to develop biosimilar products – Challenges and solutionsShantreddy Soogareddy, Associate Director External R&D, Dr. Reddy's Laboratories SA.ROUNDTABLE 3Characterisation and analytics of products on the marketTudor Arvinte, Owner, Therapeomic Inc.ROUNDTABLE 4Market accessAdam Levysohn, Sr Director Market Access Biosimilar, BiogenROUNDTABLE 5If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297ROUNDTABLE 6If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
last published: 17/Jul/18 15:35 GMT
last published: 17/Jul/18 15:35 GMT

back to speakers

Mark Your Calendars Now!
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates